Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors

Seminars in Hematology

Volumn 40, Issue 2 SUPPL. 2, 2003, Pages 11-14

  Daley, George Q ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; BCR ABL PROTEIN; CYTARABINE; IMATINIB; INTERFERON; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RAS PROTEIN; TIPIFARNIB; ANTINEOPLASTIC AGENT; FARNESYL TRANS TRANSFERASE; TRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DEHYDRATION; DIARRHEA; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; FUSION GENE; HEMATOPOIETIC STEM CELL; HUMAN; MOUSE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ONCOGENE RAS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; PATHOLOGY; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; FARNESYLTRANSTRANSFERASE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; SIGNAL TRANSDUCTION;

EID: 0037762630     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2003.50035     Document Type: Conference Paper

References (29)

1. Adjei AA, Erlichman C, Davis JN, et al: A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Res 60:1871-1877, 2000
2. Ashar H, James L, Gray K, et al: FTIs block the farnesylation of CENP-E and CENP-F, and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451-30457, 2000
3. Buser CA, Dinsmore CJ, Fernandes C, et al: High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123. Anal Biochem 290:126-137, 2001
4. Cortes JE, Albitar M, Thomas D, et al: Efficacy of the farnesyl transferase inhibitor, R115777, in chronic myeloid leukemia and other hematologic malignancies. Blood 101:1692-1697, 2002
5. Daley GQ, Ben-Neriah Y: Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. Adv Cancer Res 57:151-184, 1991
6. Daley GQ, Hoover RR, Carr D, et al: SCH66336/lonafarnib together with STI571/imatinib shows synergistic killing of BCR/ABL transformed leukemia cells. Blood 101:2070, 2002
7. Daley GQ, Van Etten RA, Baltimore D: Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci USA 88:11335-11338, 1991
8. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830, 1990
9. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
10. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
11. Ghaffari S, Wu H, Gerlach M, et al: BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells. Proc Natl Acad Sci USA 96:13186-13190, 1999
12. Gibbs JB, Graham SL, Hartman GD, et al: Farnesyltransferase inhibitors versus Ras inhibitors. Curr Opin Chem Biol 1:197-203, 1997
13. Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178, 1994
14. Hoover RR, Gerlach MJ, Koh EY, et al: Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 20:5826-5835, 2001
15. Hoover RR, Mahon FX, Melo JV, et al: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100:1068-1071, 2002
16. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
17. Karp JE, Lancet JE, Kaufmann SH, et al: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial. Blood 97:3361-3369, 2001
18. Koh E, Daley G: Functional complementation of cytokine receptor signaling by BCR/ABL, in Carella AM, Daley GQ, Eaves CJ, et al (eds): Chronic Myeloid Leukemia: Biology and Treatment. London, UK, Martin Dunitz, 2001, pp 55-72
19. Lebowitz PF, Du W, Prendergast GC: Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J Biol Chem 272:16093-16095, 1997
20. Lebowitz PF, Prendergast GC: Non-Ras targets of farnesyl-transferase inhibitors: Focus on Rho. Oncogene 17:1439-1445, 1998
21. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment ofchronic myeloid leukemia. N Engl J Med 330:820-825, 1994
22. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Long-term follow-up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 92:1541-1548, 1998
23. O'Brien SG, Guilhot F, Larson RA, et al: The IRIS study: International randomized study of interferon and low-dose Ara-C versus STI571 (imatinib) in patients with newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
24. Peters DG, Hoover RR, Gerlach MJ, et al: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97:1404-1412, 2001
25. Reichert A, Heisterkamp N, Daley GQ, et al: Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 97:1399-1403, 2001
26. Reuter CW, Morgan MA, Bergmann L: Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies? Blood 96:1655-1669, 2000
27. Shah N, Nicoll J, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
28. van Triest M, de Rooij J, Bos JL: Measurement of GTP-bound Ras-like GTPases by activation-specific probes. Methods Enzymol 333:343-348, 2001
29. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464, 1997